Walleye Capital
TBPH icon

Walleye Capital’s Theravance Biopharma TBPH Stock Holding History

Walleye Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,395
Closed -$429K – 5115
2025
Q3 		$429K Sell
29,395
-5,264
-15% -$66.5K ﹤0.01% 2740
2025
Q2 		$382K Buy
+34,659
New +$337K ﹤0.01% 2864
2022
Q3 		– Sell
-82,758
Closed -$775K – 3534
2022
Q2 		$750K Buy
82,758
+44,958
+119% +$414K 0.02% 799
2022
Q1 		$361K Buy
+37,800
New +$370K 0.01% 1199
2021
Q3 		– Sell
-16,688
Closed -$242K – 1806
2021
Q2 		$242K Buy
+16,688
New +$313K 0.01% 1014

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Walleye Capital's TBPH Position: Q4 2025 in Review

Walleye Capital sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 29,395 shares — an estimated $429K sold.

Walleye Capital first reported a position in TBPH in Q2 2021 and held it in 5 quarters. The position peaked at $750K in Q2 2022. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • Walleye Capital reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 29,395 Theravance Biopharma shares in Q4 2025, an estimated $429K.
  • Walleye Capital first reported a position in Theravance Biopharma in Q2 2021 and held it in 5 quarters.
  • Walleye Capital's Theravance Biopharma position peaked at $750K in Q2 2022.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.